Stellar chairing @music_sanela , thank you for the invitation. Great Session!

It's time already! As Abstract Chair #ASE2026 in June along with @ppsengupta1 , it is our pleasure and honor to invite you to submit an original science or case report abstract for presentation at #ASE2026 in gorgeous Colorado - deadline Jan 14. ( https://t.co/etfOMNDTkM). @ASE360

This organization remains best in class in this area.

🔥 🔥 2 state of art 🗞️ on 📍 Non-amyloid specific 📍 Amyloid specific Treatments of #ATTR 🔍What you can do with the 4 pillars & more 🔬 From stabilizers to siRNA & gene editing 🧬 @HFUAcademy 🫀 👉 https://t.co/nkummHnOwq 👉 https://t.co/R7lYBrvDtC @ESC_Journals @ehj_ed

🔥 🔥 The 2 🗞️ companion about the role of #CMR in #ATTR & its editorial by @MasriAhmadMD 🩻 Game-changer in follow-up od the disease for monitoring the treatment effect 🔬 Bone-avid myocardial scintigrafy tracers are game-changer in diagnosis but not in quantification of

A clinical trial of bisoprolol and verapamil in nHCM. As you should expect by now, BB look bad. Presented at ESC by Dr. Bjerregaard #CardioTwitter

SCOUT-HCM Trial design mava in adolescents with oHCM https://t.co/86LMikZHSj #CardioTwitter

We presented updated 2 year data from the FOREST HCM trial of aficamten in patients with non obstructive HCM #HFSA2025 >80% on 15-20 mg 80% improvement in NYHA class (of those 3/4 asymptomatic) +11 points KCCQ-CSS 0.3 proportional change in NTproBNP -5% LVEF 4 with LVEF<50%

In symptomatic obstructive hypertrophic cardiomyopathy, aficamten improved oxygen uptake and heart function and decreased symptoms more than metoprolol, with a similar incidence of adverse events. Full MAPLE-HCM phase 3 trial results and Research Summary: https://t.co/LUjGMkf5UP

New in Amyloid: Misdiagnosis of cardiac amyloidosis with scintigraphy alone is common, costly & delays proper care. Referral to amyloidosis centers is key. @BU_Amyloidosis https://t.co/JxsRpXhwYe

Since we started this initiative, things have gotten worse. We have stopped tafamidis on many more patients, but the principles are the same. Careful evaluation of ATTR-CM diagnosis is vital to avoid diagnostic and therapeutic errors. https://t.co/UOhZVTgZWR #cardiotwitter

My take home messages of #ASE2025 🌍global connections, knowledge exchange and great ideas shared in a very collegial environment ❤️New recommendation articles across the Atlantic, strengthening the collaboration EACVI-@ASE360 💡#AI is here to stay! Get on board 🔝Congress

WITHDRAW-AF RCT 📌 In👫w/ presumed AF-induced #cardiomyopathy & normalized #LVEF after SR restoration 👉 withdrawal of #HF therapy is not assoc w/ LVEF ⬇️ again in 90% of👫in the following 6-m #EPeeps #afib #HeartFailure #CardioTwitter #MedTwitter @DrMarthaGulati @JagSinghMD

The AQUATIC trial may be the most definitive trial of #ESCCOngress The common combo of ASA and OAC for pts with CAD/stent and AF is clearly been harming people. Lots. MACE worse, Death worse, Bleeding way worse. STOP THE ASA when on OAC https://t.co/OSx0UKWPXe

Really intriguing data from the phase I OLE of NI006/ALXN2220 or its new name cliramitug #CardioTwitter #ESC2025 #MedIQESCCongress

🚀 New PARACHUTE-HF results! In Chagas-related HFrEF, #sacubitrilvalsartan outperformed placebo in #PARACHUTEHF trial: • 52% higher better outcome rate • NT-proBNP ↓30.6% vs 5.5% • Fewer adverse discontinuations (6.1% vs 9.8%) 🌎💙 #CardioTwitter #ESCCongress

MAPLE-HCM Study: #Aficamten monotherapy compared to metoprolol monotherapy improves echocardiographic measures of cardiac structure and function in participants with symptomatic #oHCM https://t.co/CWJTF0r9Jh #ESCCongress #WCCardio #JACC #Echofirst @MasriAhmadMD @AnneDybro

Outcomes from the open label extension of #HELIOS-B - vutrisiran in ATTR-CM Patients originally randomized vutrisiran vs placebo 40% taf at baseline 10% total drop in taf Then open label vutrisiran #ESC2025 #cardioTwitter #MedIQESCCongress

Meeting of the leading pericardial experts in Madrid at the ESC with release of the new myocardial and pericardial guidelines @ASE360 @NBE_96 @CleClinicHVTI #ESCCongress2025

Congrats to the authors, but 2 critical points: 1) There’s no role for PYP scan in setting of + monoclonal protein. 2) “Promptly diagnosing” does not mean 1-2 months from time of suspicion. When #AL #amyloidosis is in the differential, it’s a near-emergency — every day matters.